Dianthus Therapeutics Inc. Common Stock DNTH · Stock Open Dianthus Therapeutics Inc. Common Stock in new tab
Dianthus Therapeutics Inc. Common Stock Analysis (DNTH)
Is Dianthus Therapeutics Inc. Common Stock a good investment? Dianthus Therapeutics Inc. Common Stock (DNTH) is currently trading at 106.02 USD. Market analysts have a consensus price target of 128.58 USD. This suggests a potential upside from current levels.
Earnings Schedule: Dianthus Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -4.65.
Investor FAQ
Does Dianthus Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Dianthus Therapeutics Inc. Common Stock?
Dianthus Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -4.23.
Company Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 12, 2023 | 0.060000 |
Community Discussion